NFKB1 and neoplasm: WA reduces the expression of ECM1 through the IKK/IκB/NF-κB signaling pathway to reverse the cisplatin resistance of cancer cells and to facilitate the drug resistance of the tumor microenvironment, which provides a rationale for the development of WA as a natural chemotherapeutic agent against cisplatin resistant ovarian cancer (Figure 5D).